Lu Min, Zhao Jing, Zeng Mei, Zhu AiMin, Li JinFen
Department of Pediatrics, Suzhou Research Center of Medical School, Suzhou Hospital, Affliated Hospital of Medical School, Nanjing University, Suzhou, Jiangsu, 215153, China.
Department of Child Health Care, Ezhou Central Hospital, Ezhou, Hubei, 436000, China.
Open Med (Wars). 2025 May 21;20(1):20251176. doi: 10.1515/med-2025-1176. eCollection 2025.
The aim of this study was to investigate the feasibility of the 4-week IgE/baseline IgE ratio and tryptase to predict the clinical efficacy of omalizumab in the treatment of pediatric moderate-to-severe asthma.
Moderate-to-severe asthma patients were selected, and their baseline IgE levels were recorded, and the IgE levels were tested again after 4 weeks of treatment with omalizumab to calculate the 4-week IgE/baseline IgE ratio. Serum tryptase was measured. Treatment efficacy was assessed. Patients were divided into response and non-response groups. Receiver operating characteristic curves were plotted for the sensitivity and specificity of the indices in predicting response to omalizumab treatment.
Serum total IgE levels increased to 655.89 IU/mL, serum tryptase was 5.31 ng/mL after 4 weeks of treatment, which was higher than at baseline. There was a significant difference in total serum IgE between children in response and non-response groups after 4 weeks of treatment. The response group children had a higher 4-week IgE/baseline IgE ratio, whereas tryptase was lower. Combined metrics had moderate predictive value for the efficacy of omalizumab therapy.
The 4-week IgE/baseline IgE ratio combined with tryptase can predict, to a certain extent, the clinical efficacy of omalizumab in the treatment of pediatric moderate-to-severe asthma.
本研究旨在探讨4周时的IgE/基线IgE比值和类胰蛋白酶预测奥马珠单抗治疗小儿中重度哮喘临床疗效的可行性。
选取中重度哮喘患者，记录其基线IgE水平，在用奥马珠单抗治疗4周后再次检测IgE水平以计算4周时的IgE/基线IgE比值。检测血清类胰蛋白酶。评估治疗效果。将患者分为反应组和无反应组。绘制受试者工作特征曲线以分析各指标预测奥马珠单抗治疗反应的敏感性和特异性。
治疗4周后血清总IgE水平升至655.89 IU/mL，血清类胰蛋白酶为5.31 ng/mL，高于基线水平。治疗4周后，反应组和无反应组儿童的血清总IgE存在显著差异。反应组儿童的4周IgE/基线IgE比值较高，而类胰蛋白酶较低。联合指标对奥马珠单抗治疗疗效具有中等预测价值。
4周IgE/基线IgE比值联合类胰蛋白酶在一定程度上可预测奥马珠单抗治疗小儿中重度哮喘的临床疗效。
